Giapreza (angiotensin II) significantly improved survival and reduced time on renal replacement therapy in patients with acute kidney injury.
– Announced the release of data from analyses of the impact of GIAPREZA (angiotensin II) on outcomes of a subset of patients with acute kidney injury requiring renal replacement therapy (AKI-RRT) enrolled in the ATHOS-3 (Angiotensin II for the Treatment of High Output Shock) study.
– The presentation, entitled “Outcomes in Patients with Acute Kidney Injury Receiving Angiotensin II for Vasodilatory Shock,” will take place during The 23rd International Conference on Advances in Critical Care Nephrology – AKI & CRRT 2018, being held March 6-9, 2018 in San Diego, California. The manuscript, entitled “Outcomes in patients with vasodilatory shock and renal replacement therapy treated with intravenous angiotensin II” was published online in Critical Care Medicine.“Acute kidney injury requiring dialysis associated with distributive shock, also referred to as vasodilatory shock, represents a significant medical risk for patients and a significant financial burden to the health care system,” said James Tumlin M.D., Professor of Medicine and Director of NephroNet Clinical Trials Consortium. “These analyses of the effect of angiotensin II on AKI patients requiring dialysis in the ATHOS-3 study demonstrated angiotensin II is a promising therapy to address this unmet need.”
– The presentations and manuscript detail the outcomes of patients with acute kidney injury (AKI) and vasodilatory shock enrolled in the ATHOS-3 study of GIAPREZA. In this post-hoc analysis, the data from 105 AKI patients (GIAPREZA n=45; placebo n=60) requiring renal replacement therapy (RRT) at study drug initiation were analyzed. Survival through day 28 was 53% (95% CI: 38%-67%) for the GIAPREZA group compared to 30% (95% CI: 19%-41%) for the placebo group (p = 0.012). By day 7, 38% (95% CI: 25%-54%) of patients treated with GIAPREZA discontinued RRT compared to 15% (95% CI: 8%-27%) of patients treated with placebo (p = 0.007). Mean arterial pressure (MAP) response at hour 3 was achieved in 53% (95% CI: 38%-68%) of patients treated with GIAPREZA compared to 22% (95% CI: 12%-34%) of patients treated with placebo (p = 0.001). – Source TradeTheNews.com
News: LJPC Giapreza (angiotensin II) significantly improved survival and reduced time on renal replacement therapy in patients with acute kidney injury - Source TradeTheNews.com
Time: Tuesday, March 06, 2018 14:39
Intraday Maximum Change: $0.79 - 2.49% Minutes After: 72
Latest Quote: 30 Change Since: $-0.94 - -3.13% Days Since: 134
Snapshot of company's key stats at the time of the event
Market Cap: 722,463,007 Shares Outstanding: 22,168,242 Float: 20,503,195
Day's Short Interest: 6,497,946 Short Ratio: 10.82%
Institutional Ownership: 77.7% Insider Ownership: 7.5%
LJPC - La Jolla Pharmaceutical Company
Sector: Healthcare - Industry: Biotechnology
La Jolla Pharmaceutical Co is an American biopharmaceutical company. It is focused on the discovery, development and commercialization of therapies intended to improve outcomes in patients suffering from life-threatening diseases.